239 related articles for article (PubMed ID: 35033939)
1. Targeting un-MET needs in advanced non-small cell lung cancer.
Coleman N; Harbery A; Heuss S; Vivanco I; Popat S
Lung Cancer; 2022 Feb; 164():56-68. PubMed ID: 35033939
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
3. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
4. Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Fujino T; Suda K; Mitsudomi T
Expert Opin Emerg Drugs; 2020 Sep; 25(3):229-249. PubMed ID: 32615820
[TBL] [Abstract][Full Text] [Related]
5. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
8. Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.
Lai GGY; Guo R; Drilon A; Shao Weng Tan D
Cancer Treat Rev; 2022 Nov; 110():102444. PubMed ID: 36108503
[TBL] [Abstract][Full Text] [Related]
9. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
Cortot A; Le X; Smit E; Viteri S; Kato T; Sakai H; Park K; Camidge DR; Berghoff K; Vlassak S; Paik PK
Clin Lung Cancer; 2022 May; 23(3):195-207. PubMed ID: 35272955
[TBL] [Abstract][Full Text] [Related]
10. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
12. Going After
Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
[TBL] [Abstract][Full Text] [Related]
13. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
14. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
15. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Dong Y; Xu J; Sun B; Wang J; Wang Z
Mol Diagn Ther; 2022 Mar; 26(2):203-227. PubMed ID: 35266116
[TBL] [Abstract][Full Text] [Related]
16. MET alterations in NSCLC-Current Perspectives and Future Challenges.
Remon J; Hendriks LEL; Mountzios G; García-Campelo R; Saw SPL; Uprety D; Recondo G; Villacampa G; Reck M
J Thorac Oncol; 2023 Apr; 18(4):419-435. PubMed ID: 36441095
[TBL] [Abstract][Full Text] [Related]
17. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Suzawa K; Offin M; Lu D; Kurzatkowski C; Vojnic M; Smith RS; Sabari JK; Tai H; Mattar M; Khodos I; de Stanchina E; Rudin CM; Kris MG; Arcila ME; Lockwood WW; Drilon A; Ladanyi M; Somwar R
Clin Cancer Res; 2019 Feb; 25(4):1248-1260. PubMed ID: 30352902
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
[TBL] [Abstract][Full Text] [Related]
19. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
Miao K; Zhang X; Wang H; Si X; Zhang L
Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
[TBL] [Abstract][Full Text] [Related]
20. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]